Log in

Amyris Stock Forecast, Price & News

-0.06 (-2.08 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $2.83
50-Day Range
MA: $3.44
52-Week Range
Now: $2.83
Volume8.76 million shs
Average Volume2.50 million shs
Market Capitalization$578.37 million
P/E RatioN/A
Dividend YieldN/A
Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Read More
Amyris logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
Current SymbolNASDAQ:AMRS



Sales & Book Value

Annual Sales$152.56 million
Book Value($2.17) per share


Net Income$-242,770,000.00
Net Margins-245.73%


Market Cap$578.37 million
Next Earnings Date11/5/2020 (Estimated)
-0.06 (-2.08 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Amyris (NASDAQ:AMRS) Frequently Asked Questions

How has Amyris' stock price been impacted by COVID-19?

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRS stock has decreased by 4.6% and is now trading at $2.8250.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Amyris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amyris

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Amyris

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.37. The biotechnology company had revenue of $30.01 million for the quarter, compared to analyst estimates of $35.76 million.
View Amyris' earnings history

When did Amyris' stock split? How did Amyris' stock split work?

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris updated its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220.32-220.32 million, compared to the consensus revenue estimate of $220.6 million.

What price target have analysts set for AMRS?

2 brokerages have issued twelve-month price objectives for Amyris' stock. Their forecasts range from $9.00 to $11.00. On average, they expect Amyris' share price to reach $10.00 in the next year. This suggests a possible upside of 254.0% from the stock's current price.
View analysts' price targets for Amyris

Who are some of Amyris' key competitors?

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Nokia Oyj (NOK), Sorrento Therapeutics (SRNE), Gevo (GEVO), Novavax (NVAX), AT&T (T), NVIDIA (NVDA), Pfizer (PFE) and General Electric (GE).

Who are Amyris' key executives?

Amyris' management team includes the following people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 53)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)
  • Dr. Joel R. Cherry, Pres of R&D (Age 58)

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (8.74%), RTW Investments LP (1.90%), Hudson Bay Capital Management LP (1.55%), Perceptive Advisors LLC (0.90%), Pinnacle Associates Ltd. (1.03%) and Nantahala Capital Management LLC (1.02%). Company insiders that own Amyris stock include Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang.
View institutional ownership trends for Amyris

Which major investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Pinnacle Associates Ltd., Essex Investment Management Co. LLC, UBS Group AG, Spark Investment Management LLC, Virtus ETF Advisers LLC, Baird Financial Group Inc., and Envestnet Asset Management Inc.. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang.
View insider buying and selling activity for Amyris

Which major investors are buying Amyris stock?

AMRS stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Perceptive Advisors LLC, Nantahala Capital Management LLC, FMR LLC, Monashee Investment Management LLC, Virtu Financial LLC, Bank of America Corp DE, and Algert Global LLC. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, and L John Doerr.
View insider buying and selling activity for Amyris

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $2.83.

How big of a company is Amyris?

Amyris has a market capitalization of $578.37 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe.

What is Amyris' official website?

The official website for Amyris is amyris.com.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.